luspatercept,ruxolitinib
bms,oxford biomedica,incyte,novartis
['mpnsm', '#mpn', 'lusp', 'bmsnews', 'bms']
important data presented by francesco passamonti at #eha2023 updating the results of the phase 2 study of luspatercept in mf! an important available option for our patients today while the phase 3 independence trial continues to enroll #mpnsm 
Associate Professor, Leukemia at MD Anderson; myeloproliferative neoplasm expert, NCCN panelist. Tweets reflect my own views; not necessarily my institution's.